Symbol="SUPN"
AssetType="Common Stock"
Name="Supernus Pharmaceuticals Inc"
Description="Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland."
CIK="1356576"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1550 E GUDE DR, ROCKVILLE, MD, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1742653000"
EBITDA="101575000"
PERatio="41.45"
PEGRatio="1.47"
BookValue="16.85"
DividendPerShare="0"
DividendYield="0"
EPS="0.77"
RevenuePerShareTTM="11.7"
ProfitMargin="0.0684"
OperatingMarginTTM="0.0278"
ReturnOnAssetsTTM="0.0074"
ReturnOnEquityTTM="0.0492"
RevenueTTM="634008000"
GrossProfitTTM="580017000"
DilutedEPSTTM="0.77"
QuarterlyEarningsGrowthYOY="-0.338"
QuarterlyRevenueGrowthYOY="-0.203"
AnalystTargetPrice="42.25"
TrailingPE="41.45"
ForwardPE="20.16"
PriceToSalesRatioTTM="2.911"
PriceToBookRatio="2.233"
EVToRevenue="2.97"
EVToEBITDA="16.8"
Beta="1.014"
num_52WeekHigh="42.09"
num_52WeekLow="29.06"
num_50DayMovingAverage="31.21"
num_200DayMovingAverage="35.41"
SharesOutstanding="54594000"
DividendDate="None"
ExDividendDate="None"
symbol="SUPN"
open="32.01"
high="32.28"
low="31.54"
price="31.66"
volume="237774.00"
latest_trading_day="2023-08-24"
previous_close="32.10"
change="-0.44"
change_percent="-1.3707%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="431002"
Change_recent_avg="-0.05"
Delta_recent_avg="0.97"
Variance_recent_avg="0.48"
Change_ratio_recent_avg="-0.15"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1131"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0164.jpeg"
image_negative_thumbnail_id_2="1089"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0122.jpeg"
image_neutral_thumbnail_id_1="581"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0018.jpeg"
image_neutral_thumbnail_id_2="521"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_positive_thumbnail_id_1="636"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0072.jpeg"
image_positive_thumbnail_id_2="685"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0023.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1193"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
